Introducing AMP: The Accelerating Medicines Partnership

National Institutes of Health (NIH) sent this bulletin at 02/04/2014 11:40 AM EST

Having trouble viewing this email? View it as a Web page.

You are receiving this message because you are subscribed to NIH Director's Blog for National Institutes of Health (NIH).

02/04/2014 10:15 AM EST

Lack of efficacy currently accounts for more than half of all drug failures in Phase II clinical studies (left). If AMP’s target validation efforts improve efficacy by 90% (right), the success rate will rise significantly.

It would seem like there’s never been a better time for drug development. Recent advances in genomics, proteomics, imaging, and other technologies have led to the discovery of more than a thousand risk factors for common diseases—biological changes that ought to hold promise as targets for drugs. But this deluge of new opportunities has to […]

Update Your E-mail Address | Add Subscriptions | Unsubscribe

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact NIHinfo@od.nih.gov. Before writing, please view our Frequently Asked Questions page, our A-Z Health Topics page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIH…Turning Discovery Into Health^®